This is an online portal with information on donations that were announced publicly (or have been shared with permission) that were of interest to Vipul Naik. The git repository with the code for this portal, as well as all the underlying data, is available on GitHub. All payment amounts are in current United States dollars (USD). The repository of donations is being seeded with an initial collation by Issa Rice as well as continued contributions from him (see his commits and the contract work page listing all financially compensated contributions to the site) but all responsibility for errors and inaccuracies belongs to Vipul Naik. Current data is preliminary and has not been completely vetted and normalized; if sharing a link to this site or any page on this site, please include the caveat that the data is preliminary (if you want to share without including caveats, please check with Vipul Naik). We expect to have completed the first round of development by the end of July 2024. See the about page for more details. Also of interest: pageview data on analytics.vipulnaik.com, tutorial in README, request for feedback to EA Forum.
We do not have any donor information for the donor Open Philanthopy in our system.
| Cause area | Count | Median | Mean | Minimum | 10th percentile | 20th percentile | 30th percentile | 40th percentile | 50th percentile | 60th percentile | 70th percentile | 80th percentile | 90th percentile | Maximum |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall | 6 | 2,921,000 | 2,921,000 | 2,921,000 | 2,921,000 | 2,921,000 | 2,921,000 | 2,921,000 | 2,921,000 | 2,921,000 | 2,921,000 | 2,921,000 | 2,921,000 | 2,921,000 |
| Biosecurity and pandemic preparedness | 6 | 2,921,000 | 2,921,000 | 2,921,000 | 2,921,000 | 2,921,000 | 2,921,000 | 2,921,000 | 2,921,000 | 2,921,000 | 2,921,000 | 2,921,000 | 2,921,000 | 2,921,000 |
If you hover over a cell for a given cause area and year, you will get a tooltip with the number of donees and the number of donations.
Note: Cause area classification used here may not match that used by donor for all cases.
| Cause area | Number of donations | Number of donees | Total | 2022 |
|---|---|---|---|---|
| Biosecurity and pandemic preparedness (filter this donor) | 6 | 1 | 17,526,000.00 | 17,526,000.00 |
| Total | 6 | 1 | 17,526,000.00 | 17,526,000.00 |
Skipping spending graph as there is at most one year’s worth of donations.
If you hover over a cell for a given subcause area and year, you will get a tooltip with the number of donees and the number of donations.
For the meaning of “classified” and “unclassified”, see the page clarifying this.
| Subcause area | Number of donations | Number of donees | Total | 2022 |
|---|---|---|---|---|
| Biosecurity and pandemic preparedness/COVID-19 | 6 | 1 | 17,526,000.00 | 17,526,000.00 |
| Classified total | 6 | 1 | 17,526,000.00 | 17,526,000.00 |
| Unclassified total | 0 | 0 | 0.00 | 0.00 |
| Total | 6 | 1 | 17,526,000.00 | 17,526,000.00 |
Skipping spending graph as there is at most one year’s worth of donations.
| Donee | Cause area | Metadata | Total | 2022 |
|---|---|---|---|---|
| Nigerian Institute of Medical Research (filter this donor) | 17,526,000.00 | 17,526,000.00 | ||
| Total | -- | -- | 17,526,000.00 | 17,526,000.00 |
Skipping spending graph as there is at most one year’s worth of donations.
If you hover over a cell for a given influencer and year, you will get a tooltip with the number of donees and the number of donations.
For the meaning of “classified” and “unclassified”, see the page clarifying this.
| Influencer | Number of donations | Number of donees | Total | 2022 |
|---|---|---|---|---|
| Jacob Trefethen | 6 | 1 | 17,526,000.00 | 17,526,000.00 |
| Classified total | 6 | 1 | 17,526,000.00 | 17,526,000.00 |
| Unclassified total | 0 | 0 | 0.00 | 0.00 |
| Total | 6 | 1 | 17,526,000.00 | 17,526,000.00 |
Skipping spending graph as there is at most one year’s worth of donations.
Sorry, we couldn't find any disclosures information.
If you hover over a cell for a given country and year, you will get a tooltip with the number of donees and the number of donations.
For the meaning of “classified” and “unclassified”, see the page clarifying this.
| Country | Number of donations | Number of donees | Total | 2022 |
|---|---|---|---|---|
| Nigeria | 6 | 1 | 17,526,000.00 | 17,526,000.00 |
| Classified total | 6 | 1 | 17,526,000.00 | 17,526,000.00 |
| Unclassified total | 0 | 0 | 0.00 | 0.00 |
| Total | 6 | 1 | 17,526,000.00 | 17,526,000.00 |
Skipping spending graph as there is at most one year’s worth of donations.
There are no documents associated with this donor.
Graph of top 10 donees (for donations with known year of donation) by amount, showing the timeframe of donations
| Donee | Amount (current USD) | Amount rank (out of 6) | Donation date | Cause area | URL | Influencer | Notes |
|---|---|---|---|---|---|---|---|
| Nigerian Institute of Medical Research | 2,921,000.00 | 1 | Biosecurity and pandemic preparedness/COVID-19 | https://www.openphilanthropy.org/focus/global-catastrophic-risks/biosecurity/nigerian-institute-of-medical-research-covid-19-fractional-dosing-trial | Jacob Trefethen | Intended use of funds (category): Direct project expenses Intended use of funds: Grant "to support a safety and immunogenicity trial in adults in Nigeria of fractional doses of the AstraZeneca, Moderna, and Johnson & Johnson COVID-19 vaccines." Donor reason for selecting the donee: The grant page says: "The trial has the potential to indicate that doses of these vaccines that are a quarter or half the size of standard doses promote “non-inferior” immune responses. If non-inferiority can be established, this could allow many people to be vaccinated against COVID-19 sooner despite limited supplies, reducing deaths and other harms from the pandemic." Donor reason for donating at this time (rather than earlier or later): The grant is made two years after the start of the COVID-19 pandemic, and about a year after the initial release of the vaccines being tested. The rise of variants such as delta and omicron in the past year has led to interest in booster doses, meaning that ongoing supply of the vaccine may be needed. Other notes: Affected countries: Nigeria. |
|
| Nigerian Institute of Medical Research | 2,921,000.00 | 1 | Biosecurity and pandemic preparedness/COVID-19 | https://www.openphilanthropy.org/focus/global-catastrophic-risks/biosecurity/nigerian-institute-of-medical-research-covid-19-fractional-dosing-trial | Jacob Trefethen | Intended use of funds (category): Direct project expenses Intended use of funds: Grant "to support a safety and immunogenicity trial in adults in Nigeria of fractional doses of the AstraZeneca, Moderna, and Johnson & Johnson COVID-19 vaccines." Donor reason for selecting the donee: The grant page says: "The trial has the potential to indicate that doses of these vaccines that are a quarter or half the size of standard doses promote “non-inferior” immune responses. If non-inferiority can be established, this could allow many people to be vaccinated against COVID-19 sooner despite limited supplies, reducing deaths and other harms from the pandemic." Donor reason for donating at this time (rather than earlier or later): The grant is made two years after the start of the COVID-19 pandemic, and about a year after the initial release of the vaccines being tested. The rise of variants such as delta and omicron in the past year has led to interest in booster doses, meaning that ongoing supply of the vaccine may be needed. Other notes: Affected countries: Nigeria. |
|
| Nigerian Institute of Medical Research | 2,921,000.00 | 1 | Biosecurity and pandemic preparedness/COVID-19 | https://www.openphilanthropy.org/focus/global-catastrophic-risks/biosecurity/nigerian-institute-of-medical-research-covid-19-fractional-dosing-trial | Jacob Trefethen | Intended use of funds (category): Direct project expenses Intended use of funds: Grant "to support a safety and immunogenicity trial in adults in Nigeria of fractional doses of the AstraZeneca, Moderna, and Johnson & Johnson COVID-19 vaccines." Donor reason for selecting the donee: The grant page says: "The trial has the potential to indicate that doses of these vaccines that are a quarter or half the size of standard doses promote “non-inferior” immune responses. If non-inferiority can be established, this could allow many people to be vaccinated against COVID-19 sooner despite limited supplies, reducing deaths and other harms from the pandemic." Donor reason for donating at this time (rather than earlier or later): The grant is made two years after the start of the COVID-19 pandemic, and about a year after the initial release of the vaccines being tested. The rise of variants such as delta and omicron in the past year has led to interest in booster doses, meaning that ongoing supply of the vaccine may be needed. Other notes: Affected countries: Nigeria. |
|
| Nigerian Institute of Medical Research | 2,921,000.00 | 1 | Biosecurity and pandemic preparedness/COVID-19 | https://www.openphilanthropy.org/focus/global-catastrophic-risks/biosecurity/nigerian-institute-of-medical-research-covid-19-fractional-dosing-trial | Jacob Trefethen | Intended use of funds (category): Direct project expenses Intended use of funds: Grant "to support a safety and immunogenicity trial in adults in Nigeria of fractional doses of the AstraZeneca, Moderna, and Johnson & Johnson COVID-19 vaccines." Donor reason for selecting the donee: The grant page says: "The trial has the potential to indicate that doses of these vaccines that are a quarter or half the size of standard doses promote “non-inferior” immune responses. If non-inferiority can be established, this could allow many people to be vaccinated against COVID-19 sooner despite limited supplies, reducing deaths and other harms from the pandemic." Donor reason for donating at this time (rather than earlier or later): The grant is made two years after the start of the COVID-19 pandemic, and about a year after the initial release of the vaccines being tested. The rise of variants such as delta and omicron in the past year has led to interest in booster doses, meaning that ongoing supply of the vaccine may be needed. Other notes: Affected countries: Nigeria. |
|
| Nigerian Institute of Medical Research | 2,921,000.00 | 1 | Biosecurity and pandemic preparedness/COVID-19 | https://www.openphilanthropy.org/focus/global-catastrophic-risks/biosecurity/nigerian-institute-of-medical-research-covid-19-fractional-dosing-trial | Jacob Trefethen | Intended use of funds (category): Direct project expenses Intended use of funds: Grant "to support a safety and immunogenicity trial in adults in Nigeria of fractional doses of the AstraZeneca, Moderna, and Johnson & Johnson COVID-19 vaccines." Donor reason for selecting the donee: The grant page says: "The trial has the potential to indicate that doses of these vaccines that are a quarter or half the size of standard doses promote “non-inferior” immune responses. If non-inferiority can be established, this could allow many people to be vaccinated against COVID-19 sooner despite limited supplies, reducing deaths and other harms from the pandemic." Donor reason for donating at this time (rather than earlier or later): The grant is made two years after the start of the COVID-19 pandemic, and about a year after the initial release of the vaccines being tested. The rise of variants such as delta and omicron in the past year has led to interest in booster doses, meaning that ongoing supply of the vaccine may be needed. Other notes: Affected countries: Nigeria. |
|
| Nigerian Institute of Medical Research | 2,921,000.00 | 1 | Biosecurity and pandemic preparedness/COVID-19 | https://www.openphilanthropy.org/focus/global-catastrophic-risks/biosecurity/nigerian-institute-of-medical-research-covid-19-fractional-dosing-trial | Jacob Trefethen | Intended use of funds (category): Direct project expenses Intended use of funds: Grant "to support a safety and immunogenicity trial in adults in Nigeria of fractional doses of the AstraZeneca, Moderna, and Johnson & Johnson COVID-19 vaccines." Donor reason for selecting the donee: The grant page says: "The trial has the potential to indicate that doses of these vaccines that are a quarter or half the size of standard doses promote “non-inferior” immune responses. If non-inferiority can be established, this could allow many people to be vaccinated against COVID-19 sooner despite limited supplies, reducing deaths and other harms from the pandemic." Donor reason for donating at this time (rather than earlier or later): The grant is made two years after the start of the COVID-19 pandemic, and about a year after the initial release of the vaccines being tested. The rise of variants such as delta and omicron in the past year has led to interest in booster doses, meaning that ongoing supply of the vaccine may be needed. Other notes: Affected countries: Nigeria. |
Sorry, we couldn't find any similar donors.